STAT

SEPTEMBER 5, 2023

Health care leaders and technology companies are investing heavily in large language models, a powerful class of deep learning models that are trained on vast troves of data. But while enthusiasm for generative AI is high and research is booming, it’s just starting to gain a toehold in clinical settings. Generative AI could be a revolution in health care — but along the way, it will have to address concerns about whether tools meet standards of safety, privacy, equity, and practica

Hospitals 356

Hospitals 356

PharmaVoice

SEPTEMBER 5, 2023

Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

265

265

STAT

SEPTEMBER 5, 2023

University of California graduate students were thrilled last December when they won what they thought were big pay increases after an unprecedented strike. Most of them could expect a 10% salary increase the first year of the new three-year contract, the university system said. But students contend it hasn’t worked out that way. Graduate students on some of the academic system’s 10 campuses are accusing their universities of wage theft, claiming they’re using sleight of han

Documentation 349

Documentation 349

PharmaVoice

SEPTEMBER 5, 2023

Explore four modern tech capabilities designed to help decrease cycle times, improve processes and compliance and mitigate site burdens.

246

246

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 5, 2023

The world’s largest technology companies are racing to build generative AI into every corner of health and medicine. Microsoft has formed an alliance with the electronic health records vendor Epic to wire the technology into dozens of health software products. Google is infusing it into tools used by hospitals to collect and organize data on millions of patients.

Hospitals 333

Hospitals 333

The Pharmacist

SEPTEMBER 5, 2023

Community pharmacies have been issued with guidance that they can display to help patients keep themselves and their medicines safe in the heat. This comes as the UK Health Security Agency (UKHSA) and the Met Office issued an amber heat alert effective today for all of England except the North East, which has been issued […] The post Guidance issued for pharmacies amid amber heat alert appeared first on The Pharmacist.

Community Pharmacies 111

Community Pharmacies 111

BioPharma Dive

SEPTEMBER 5, 2023

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

126

126

STAT

SEPTEMBER 5, 2023

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO. The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl

320

320

Drug Patent Watch

SEPTEMBER 5, 2023

Pharmacists play a crucial role in drug repurposing due to the vast amount of opportunities that exist in this innovative approach. Drug development and registration can be costly, time-consuming, and… The post Pharmacists Can Play Key Role in Drug Repurposing appeared first on DrugPatentWatch - Make Better Decisions.

Drug Development 111

Drug Development 111

STAT

SEPTEMBER 5, 2023

Everyone has things that, looking back, they would have done differently in the early days of 2020, had they known how the Covid-19 pandemic would tear across the globe. But those regrets may be particularly poignant for global leaders whose actions (or lack thereof) had direct impacts on how Covid-19 spread. Joanne Liu, a professor at McGill University’s School of Population and Global Health and former international president of Doctors Without Borders, has some advice for those leaders

317

317

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

SEPTEMBER 5, 2023

The artificial intelligence tool ChatGPT shows great promise in areas such as drug counselling but falls short of pharmacists' skills across a range of clinical practice categories, according to a study by Chinese researchers. To date, ChatGPT has been studied in several different areas of healthcare but is not always very effective. For instance, it […] The post Could ChatGPT replace pharmacists?

103

103

STAT

SEPTEMBER 5, 2023

The term for a patient who lists their questions was likely coined in the late 19th century in the clinic of Jean-Martin Charcot at the Salpêtrière. Known as la maladie du petit papier , or the illness of the little paper, the derogatory descriptor was inherently feminine and usually reserved for hypochondriacs making a laundry list of their purported ailments.

Hospitals 304

Hospitals 304

Pharma Times

SEPTEMBER 5, 2023

Candidate ESO-101 will treat participating patients across five European countries - News - PharmaTimes

138

138

STAT

SEPTEMBER 5, 2023

The recently approved RSV vaccines have been celebrated as key public health tools, but some vaccine experts have lamented one aspect of the trials that led to their approval — namely, that older adults were largely left out of them. Among adults, RSV poses the biggest threat to the oldest seniors and people with certain preexisting health conditions.

Vaccines 297

Vaccines Nursing Homes 297

Pharma Times

SEPTEMBER 5, 2023

The funding will boost the University of Nottingham spinout’s development of bone regeneration treatment - News - PharmaTimes

120

120

STAT

SEPTEMBER 5, 2023

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences.  Sign up to get this newsletter  delivered in your inbox every Tuesday and Thursday.

Hospitals 245

Hospitals 245

BioPharma Dive

SEPTEMBER 5, 2023

The announcement marks progress for Beam after trial delays, and is the first time in the U.S. that a patient has received a base editing treatment.

117

117

Pharmaceutical Technology

SEPTEMBER 5, 2023

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

119

119

BioPharma Dive

SEPTEMBER 5, 2023

The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.

106

106

Express Pharma

SEPTEMBER 5, 2023

The Drugs Controller General of India (DCGI) has issued an advisory urging patients and healthcare professionals against the use of Digene Gel post the voluntary recall initiated by Abbott. Recommending an immediate halt in its use, the advisory states, “Healthcare professionals should promptly report any suspicious cases of adverse events linked to this product.” The advisory strongly advises consumers and patients to discontinue the use of Digene gel manufactured at Abbott’s

102

102

The Pharmacist

SEPTEMBER 5, 2023

There are no known supply issues with Wegovy, a weekly semaglutide weight-loss injection that launched in the UK this week, the government has said. But manufacturer Novo Nordisk said yesterday that it expects supply of the drug to be ‘constrained for the foreseeable future’. This comes amid ongoing shortages and prescribing constraints for another semaglutide […] The post ‘No known’ Wegovy supply issues, says DHSC appeared first on The Pharmacist.

93

93

Express Pharma

SEPTEMBER 5, 2023

Amgen’s olpasiran, a small interfering RNA (siRNA), is making strides in reducing Lp(a) levels significantly in patients with cardiovascular disease. This is noteworthy as elevated Lp(a) is considered a potent risk factor for heart disease and stroke. It also underscores olpasiran’s potential to address a vital treatment gap, representing a pivotal advancement in the realm of dyslipidemia, according to GlobalData.

97

97

European Pharmaceutical Review

SEPTEMBER 5, 2023

Novo Nordisk’s semaglutide injection Wegovy ® is now available as a treatment for obesity in the UK. The pharmaceutical company stated it believed that the launch of Wegovy will help provide an additional option to support people living with obesity in the UK. The semaglutide injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management.

Labelling 89

Labelling Pharmaceutical Companies Pharmaceutical Companies 89

Pharmaceutical Technology

SEPTEMBER 5, 2023

A new set of European Society of Cardiology (ESC) guidelines was shared at the 2023 ESC conference in Amsterdam, Netherlands.

98

98

European Pharmaceutical Review

SEPTEMBER 5, 2023

The UK government is investing £5.5 million to establish a Medicines Manufacturing Skills Centre of Excellence. The centre will help the UK life sciences sector to have the right talent to drive innovation to support the UK in its response to future health emergencies. It will build on existing infrastructure and best practice, and deliver sustainable, end-to-end training provision.

Packaging 86

Packaging Pharmaceutical Manufacturing 86

Pharmaceutical Technology

SEPTEMBER 5, 2023

The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant) for the prophylaxis of migraine in adults.

98

98

European Pharmaceutical Review

SEPTEMBER 5, 2023

Potential of real-time measurement through miniaturisation of a process analytical technology (PAT) technique has been reported in a Biotechnology and Bioengineering paper. A micromixer was able to effectively detect aggregation in offline measurement-validated samples. The authors described how a PAT fluorescent dye (FD)-based microfluidic sensor was successfully implemented in an integrated downstream process.

83

83

Outsourcing Pharma

SEPTEMBER 5, 2023

CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study â 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis (PBC)' known as IDEAL.

74

74

European Pharmaceutical Review

SEPTEMBER 5, 2023

It is now five years since the first reports of N -nitrosodimethylamine (NDMA) contamination in valsartan active pharmaceutical ingredient (API). Over that time-period the issue has morphed from an API contamination issue of sartans (and other APIs), into concerns about API-related nitrosamines in drug products, ie, nitrosamine drug substance‑related impurities (NDSRIs).

79

79

PharmaTech

SEPTEMBER 5, 2023

Advanced analytical tools generate more data in today’s labs than ever before.

105

105

BioPharma Dive

SEPTEMBER 5, 2023

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

68

68

Pharmafile

SEPTEMBER 5, 2023

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), for the prophylaxis of migraine in adult patients who have had at least four migraine days each month. This marketing authorisation follows data from two phase 3 clinical trials assessing the drug in a 60mg […] The post AbbVie’s Aquipta receives MHRA marketing authorisation appeared first on Pharmafile.

63

63

pharmaphorum

SEPTEMBER 5, 2023

UK women cleared to sue Bayer over Essure contraceptive Phil.

102

102

World Pharma News

SEPTEMBER 5, 2023

A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period.

Immunity 65

Immunity Immunization 65

Drug Patent Watch

SEPTEMBER 5, 2023

Annual Drug Patent Expirations for PHEXXI Phexxi is a drug marketed by Evofem Inc and is included in one NDA. It is available from one supplier. There are four patents… The post New patent expiration for Evofem Inc drug PHEXXI appeared first on DrugPatentWatch - Make Better Decisions.

59

59